Small, Dense LDL and ApoB: What your cholesterol numbers mean today

Small dense LDL are more atherogenic because they infiltrate arterial walls and oxidize more easily. High triglycerides often accompany sdLDL. ApoB and LDL-P measure particle number and can reveal risk missed by LDL-C. Labs offer direct sdLDL/LDL-P testing (NMR, ion mobility) and ApoB assays. Discuss results with your clinician; lifestyle changes and statins are mainstays of treatment.

Why cholesterol numbers matter

Cholesterol remains a key marker in assessing heart and stroke risk. Modern testing has taught us that not all cholesterol is the same: HDL is generally protective, while LDL carries cholesterol that can build up in artery walls. The problem arises when LDL particles are out of balance and form plaque that narrows arteries, increasing the risk of heart attack and stroke.

What is small dense LDL (sdLDL)?

Small dense LDL (sdLDL) refers to LDL particles that are smaller and denser than average. Because of their size and composition, sdLDL particles more easily penetrate the arterial wall and are more susceptible to oxidation - two processes that accelerate atherosclerosis. Observational studies have linked a predominance of sdLDL with higher rates of coronary disease compared with larger, buoyant LDL particles.

Triglycerides, ApoB and why particle number matters

High triglycerides often accompany an increase in sdLDL. That relationship matters because traditional LDL-C (the cholesterol mass carried by LDL) does not directly measure particle number. Apolipoprotein B (ApoB) counts the number of atherogenic particles (each LDL particle carries one ApoB). Many clinicians now view ApoB - or LDL particle number (LDL-P, measured by NMR or ion mobility) - as a clearer indicator of risk in patients with high triglycerides, diabetes, or metabolic syndrome. ¹

Using the LDL/ApoB ratio

Researchers including Hirano have proposed using the ratio of LDL-C to ApoB to infer the predominance of sdLDL. A lower ratio suggests more cholesterol carried by a larger number of smaller particles. A commonly cited cutoff in older studies is an LDL-C/ApoB ratio below about 1.2 as suggesting sdLDL predominance. Units and exact thresholds vary by laboratory, so interpret this ratio only with lab-specific units and clinical context. ²

How sdLDL is measured today

Direct tests for sdLDL or LDL particle number are available in many commercial labs. Methods include nuclear magnetic resonance (NMR) lipoprofile, ion mobility, and gradient gel electrophoresis. ApoB is widely available and often used as a practical surrogate for particle burden.

What to do if you have sdLDL or high ApoB

Discuss results with your clinician. In general, evidence-based approaches to lower atherogenic particle number include lifestyle steps (weight loss, reduce refined carbs and sugars, increase physical activity) and pharmacologic therapy when indicated (statins remain first-line). Other agents (fibrates, high-dose omega-3s, PCSK9 inhibitors) may be considered based on overall risk and guidelines. Your clinician can advise tests to monitor response (LDL-C, ApoB, or LDL-P).

Bottom line

sdLDL and high ApoB identify a higher burden of atherogenic particles that may not be obvious from LDL-C alone. If you have high triglycerides, diabetes, or unexplained residual risk on treatment, ask your clinician about ApoB or LDL-P testing and targeted steps to lower particle number. ³

1. Verify the quantitative risk estimate that sdLDL increases coronary heart disease risk 'threefold' from Hirano or other studies.
2. Confirm the LDL-C/ApoB cutoff value (around 1.2) including the units used for LDL-C and ApoB in the original Hirano publications and how labs report it.
3. Verify current guideline recommendations (ACC/AHA, ESC/EAS or other major societies as of 2025) regarding when to use ApoB or LDL-P instead of or alongside LDL-C.
4. Confirm details and prevalence of modern laboratory methods for sdLDL/LDL-P measurement (NMR, ion mobility, gradient gel) and their availability in routine clinical practice.